Non-Small Cell Lung Cancer - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Non-Small Cell Lung Cancer > What Your Doctor is Reading About Non-Small Cell Lung Cancer > Review Articles

Review Articles

1. Chemotherapy and antiangiogenic agents in non-small-cell lung cancer.

Author: Horn L; Sandler A;
Institution: Department of Medicine, University of Toronto, ON, Canada.
Journal: Clin Lung Cancer. 2007 Feb;8 Suppl 2:S68-73.
Abstract URL: Click here to view abstract

2. Proteasome inhibitors in lung cancer.

Author: Scagliotti G; Scagliotti G;
Institution: University of Torino, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital-Regione Gonzole 10, 10043 Orbassano, Torino, Italy. scagliotti@ihnet.it
Journal: Crit Rev Oncol Hematol. 2006 Jun;58(3):177-89. Epub 2006 Jan 19.
Abstract URL: Click here to view abstract

3. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials.

Author: Wright G; Manser RL; Byrnes G; Hart D; Campbell DA;
Institution: Cardiothoracic Care Centre, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
Journal: Thorax. 2006 Jul;61(7):597-603. Epub 2006 Jan 31.
Abstract URL: Click here to view abstract

4. The role of induction therapy for resectable non-small cell lung cancer.

Author: Stinchcombe TE; Socinski MA;
Institution: Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA. Thomas_Stinchcombe@med.unc.edu
Journal: Drugs. 2007;67(3):321-32.
Abstract URL: Click here to view abstract

5. New targets for non-small-cell lung cancer therapy.

Author: Alvarez M; Roman E; Santos ES; Raez LE;
Institution: University of Miami Miller's School of Medicine, The William Harrington Latin American Training Program (WHLTP), Division of Hematology - Medical Oncology, Sylvester Comprehensive Cancer Center, 1475 NW 12 Avenue, Miami, FL 33136, USA.
Journal: Expert Rev Anticancer Ther. 2007 Oct;7(10):1423-37.
Abstract URL: Click here to view abstract

6. Targeted therapies in lung cancer.

Author: Besse B; Ropert S; Soria JC;
Institution: Department of Medicine, Institut Gustave Roussy, Villejuif.
Journal: Ann Oncol. 2007 Jul;18 Suppl 9:ix135-42.

7. Video assisted thoracoscopic surgery and lobectomy, sublobar resection, radiofrequency ablation, and stereotactic radiosurgery: advances and controversies in the management of early stage non-small cell lung cancer.

Author: Pennathur A; Abbas G; Christie N; Landreneau R; Luketich JD;
Institution: Heart, Lung, and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.
Journal: Curr Opin Pulm Med. 2007 Jul;13(4):267-70.
Abstract URL: Click here to view abstract

8. Vaccine therapy in non-small-cell lung cancer.

Author: Albright C; Garst J;
Institution: Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. Albri015@mc.duke.edu
Journal: Curr Oncol Rep. 2007 Jul;9(4):241-6.
Abstract URL: Click here to view abstract

9. The role of surgery in the treatment of stage III non-small-cell lung cancer.

Author: Gallo AE; Donington JS;
Institution: Department of Cardiothoracic Surgery, Stanford University School of Medicine, Falk CVRB, Stanford, CA 94303, USA.
Journal: Curr Oncol Rep. 2007 Jul;9(4):247-54.
Abstract URL: Click here to view abstract

10. Adjuvant chemotherapy for non-small cell lung cancer.

Author: Solomon B; Bunn PA Jr;
Institution: Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia.
Journal: Cancer Invest. 2007 Jun;25(4):217-25.
Abstract URL: Click here to view abstract

11. Current treatment paradigms for locally advanced non-small cell lung cancer.

Author: Rigas JR; Kelly K;
Institution: Dartmouth Medical School, Lebanon, NH 03756, USA. james.r.rigas@dartmouth.edu
Journal: J Thorac Oncol. 2007 Jun;2 Suppl 2:S77-85.
Abstract URL: Click here to view abstract

12. Amrubicin for non-small-cell lung cancer and small-cell lung cancer.

Author: Kurata T; Okamoto I; Tamura K; Fukuoka M; Kurata T; Okamoto I; Tamura K; Fukuoka M;
Institution: Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. ctc002@poh.osaka-med.ac.jp
Journal: Invest New Drugs. 2007 Oct;25(5):499-504. Epub 2007 Jul 13.
Abstract URL: Click here to view abstract

13. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer.

Author: Burdett SS; Stewart LA; Rydzewska L;
Institution: MRC Clinical Trials Unit, Meta-Analysis Group, 222 Euston Road, London, UK, NW1 2DA. sb@ctu.mrc.ac.uk
Journal: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006157.
Abstract URL: Click here to view abstract

14. Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer.

Author: Perez-Soler R;
Institution: Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467-2490, USA. rperezso@montefiore.org
Journal: Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4589-92.
Abstract URL: Click here to view abstract

15. Bevacizumab in non small cell lung cancer.

Author: Sandler A;
Institution: Thoracic Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232-6307, USA. alan.sandler@vanderbilt.edu
Journal: Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4613-6.
Abstract URL: Click here to view abstract

16. Developments in the treatment of non-small cell lung cancer.

Author: Gkiozos I; Charpidou A; Syrigos K;
Institution: Athens University School of Medicine, Head, Oncology Unit, Third Department of Medicine Athens School of Medicine, Building Z, Sotiria General Hospital, Mesogion 152, 115 27 Athens, Greece.
Journal: Anticancer Res. 2007 Jul-Aug;27(4C):2823-7.
Abstract URL: Click here to view abstract

17. Emerging drugs for non-small-cell lung cancer.

Author: Felip E; Santarpia M; Rosell R;
Institution: Institut Catala d'Oncologia, Hospital Germans Trias I Pujol, Ctra. Canyet. s/n, 08916 Badalona, Barcelona, Spain.
Journal: Expert Opin Emerg Drugs. 2007 Sep;12(3):449-60.
Abstract URL: Click here to view abstract

18. Molecular predictors of chemotherapy response in non-small-cell lung cancer.

Author: Gray J; Simon G; Bepler G;
Institution: H Lee Moffitt Cancer Center & Research Institute, Division of Thoracic Oncology, Tampa, Florida 33612, USA. jhanelle.gray@moffitt.org
Journal: Expert Rev Anticancer Ther. 2007 Apr;7(4):545-9.
Abstract URL: Click here to view abstract

19. Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future.

Author: Potti A; Ganti AK;
Institution: Duke Institute for Genome Sciences and Policy, Division of Hematology, Duke University Medical Center, Box #3382, CIEMAS, Durham, NC 27710, USA. anil.potti@duke.edu
Journal: Expert Opin Biol Ther. 2006 Jul;6(7):709-16.
Abstract URL: Click here to view abstract

20. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.

Author: Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W;
Institution: Department of Internal Medicine, Division of Hematology and Oncology, Medical University Innsbruck, Austria.
Journal: Curr Cancer Drug Targets. 2006 Jun;6(4):271-94.
Abstract URL: Click here to view abstract

21. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Author: Janne PA; Johnson BE;
Institution: Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. pjanne@partners.org
Journal: Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s.
Abstract URL: Click here to view abstract

22. The evolving role of cetuximab in non-small cell lung cancer.

Author: Lilenbaum RC;
Institution: Thoracic Oncology Program, Mount Sinai Cancer Center, Miami Beach, Florida 33140, USA. rlilenba@salick.com
Journal: Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4432s-4435s.
Abstract URL: Click here to view abstract

23. Adjuvant therapy in the elderly: making the right decision.

Author: Muss HB; Biganzoli L; Sargent DJ; Aapro M;
Institution: University of Vermont and Vermont Cancer Center, Burlington, VT 05401, USA. hyman.muss@uvm.edu
Journal: J Clin Oncol. 2007 May 10;25(14):1870-5.
Abstract URL: Click here to view abstract

24. Where next for gefitinib in patients with lung cancer?

Author: Blackhall F; Ranson M; Thatcher N;
Institution: Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust Manchester, M20 4BX, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uk
Journal: Lancet Oncol. 2006 Jun;7(6):499-507.
Abstract URL: Click here to view abstract

25. Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status.

Author: Stinchcombe TE; Lee CB; Socinski MA;
Institution: Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill 27599-7305, USA.
Journal: Clin Lung Cancer. 2006 May;7 Suppl 4:S111-7.
Abstract URL: Click here to view abstract

26. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.

Author: Ferraldeschi R; Thatcher N; Lorigan P; Ferraldeschi R; Thatcher N; Lorigan P;
Institution: Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. roberta_ferraldeschi@yahoo.com
Journal: Expert Rev Anticancer Ther. 2007 May;7(5):635-40.
Abstract URL: Click here to view abstract

27. Angiogenesis inhibitors in lung cancer: a promise fulfilled.

Author: Dy GK; Adjei AA;
Institution: Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Journal: Clin Lung Cancer. 2006 May;7 Suppl 4:S145-9.
Abstract URL: Click here to view abstract

28. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.

Author: Rajeswaran A; Trojan A; Burnand B; Giannelli M;
Institution: Faculty of Biology and Medicine, University of Lausanne, Switzerland.
Journal: Lung Cancer. 2008 Jan;59(1):1-11. Epub 2007 Aug 27.
Abstract URL: Click here to view abstract

29. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer.

Author: Lo SS; Fakiris AJ; Papiez L; Abdulrahman R; McGarry RC; Henderson MA; Forquer JA; Hoopes D; Timmerman RD;
Institution: Ohio State University Medical Center, Department of Radiation Medicine, Arthur G James Cancer Hospital, 300 West 10th Avenue, Suite 088A, Columbus, OH 43210, USA. simon.lo@osumc.edu
Journal: Expert Rev Anticancer Ther. 2008 Jan;8(1):87-98.
Abstract URL: Click here to view abstract

30. Molecular biologic staging of lung cancer.

Author: D'Amico TA;
Institution: Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. damic001@mc.duke.edu
Journal: Ann Thorac Surg. 2008 Feb;85(2):S737-42.
Abstract URL: Click here to view abstract

31. Radiofrequency ablation to treat non-small cell lung cancer and pulmonary metastases.

Author: Fernando HC;
Institution: Department of Cardiothoracic Surgery, Boston Medical Center, Boston University, Boston, Massachusetts 02118, USA. hiran.Fernando@bmc.org
Journal: Ann Thorac Surg. 2008 Feb;85(2):S780-4.
Abstract URL: Click here to view abstract

32. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer.

Author: Tanvetyanon T; Soares HP; Djulbegovic B; Jacobsen PB; Bepler G;
Institution: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA. tanvett@moffitt.org
Journal: J Thorac Oncol. 2007 Dec;2(12):1091-7.
Abstract URL: Click here to view abstract

33. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.

Author: Keedy VL; Sandler AB;
Institution: Vanderbilt-Ingram Cancer Center, Vanderbilt University, Department of Medicine, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37272-6307, USA. vicki.keedy@vanderbilt.edu
Journal: Cancer Sci. 2007 Dec;98(12):1825-30. Epub 2007 Sep 24.
Abstract URL: Click here to view abstract

34. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review.

Author: Ung YC; Maziak DE; Vanderveen JA; Smith CA; Gulenchyn K; Lacchetti C; Evans WK;
Institution: Odette Cancer Centre and University of Toronto, Toronto, ON, Canada.
Journal: J Natl Cancer Inst. 2007 Dec 5;99(23):1753-67. Epub 2007 Nov 27.
Abstract URL: Click here to view abstract

35. Cetuximab in non-small cell lung cancer.

Author: Ademuyiwa FO; Hanna N;
Institution: Indiana University School of Medicine, Division of Hematology/Oncology, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA. fademuyi@iupui.edu
Journal: Expert Opin Biol Ther. 2008 Jan;8(1):107-13.
Abstract URL: Click here to view abstract

36. Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer.

Author: Simon GR; Begum M; Bepler G;
Institution: Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, MRC-4W, Tampa, FL 33612, USA. george.simon@moffitt.org
Journal: Future Oncol. 2008 Feb;4(1):51-9.
Abstract URL: Click here to view abstract

37. A critical look at the role of chemotherapy in older patients with non-small cell lung cancer.

Author: Jatoi A; Aranguren D;
Institution: Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Journal: J Thorac Oncol. 2007 Jan;2(1):83-90.
Abstract URL: Click here to view abstract

38. Surgery for bronchioloalveolar carcinoma and "very early" adenocarcinoma: an evolving standard of care?

Author: Rusch VW; Tsuchiya R; Tsuboi M; Pass HI; Grunenwald D; Goldstraw P;
Institution: Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. ruschv@mskcc.org
Journal: J Thorac Oncol. 2006 Nov;1(9 Suppl):S27-31.
Abstract URL: Click here to view abstract

39. A review of vaccine clinical trials for non-small cell lung cancer.

Author: Nemunaitis J; Nemunaitis J; Nemunaitis J; Nemunaitis J;
Institution: Mary Crowley Medical Research Center, 60th Floor, 1717 Main St, Dallas, Texas 75201, USA. jnemunaitis@mcmrc.com
Journal: Expert Opin Biol Ther. 2007 Jan;7(1):89-102.
Abstract URL: Click here to view abstract

40. Antiangiogenic therapy in nonsmall cell lung cancer.

Author: Gutierrez M; Giaccone G;
Institution: Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
Journal: Curr Opin Oncol. 2008 Mar;20(2):176-82.
Abstract URL: Click here to view abstract

41. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer.

Author: Kosteva J; Langer C;
Institution: Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Journal: Curr Opin Oncol. 2008 Mar;20(2):155-61.
Abstract URL: Click here to view abstract

42. Remediastinoscopy.

Author: Van Schil P; De Waele M; Hendriks J; Lauwers P;
Institution: Department of Thoracic and Vascular Surgery, University Hospital of Antwerp, Antwerp, Belgium. paul.van.schil@uza.be
Journal: J Thorac Oncol. 2007 Apr;2(4):365-6.
Abstract URL: Click here to view abstract

43. Management of unresected stage III non-small cell lung cancer: a systematic review.

Author: Okawara G; Mackay JA; Evans WK; Ung YC;
Institution: Juravinski Cancer Centre at Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada.
Journal: J Thorac Oncol. 2006 May;1(4):377-93.
Abstract URL: Click here to view abstract

44. Salvage therapy in patients with advanced non-small cell lung cancer.

Author: Bedano PM; Hanna NH;
Institution: Department of Medicine, Division of Oncology, Indiana University, Indianapolis, Indiana 46202, USA. pabedano@iupui.edu
Journal: J Thorac Oncol. 2006 Jul;1(6):582-7.
Abstract URL: Click here to view abstract

45. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer.

Author: Burdett S; Stewart LA; Rydzewska L;
Institution: Meta-analysis Group, MRC Clinical Trials Unit, London, United Kingdom. sb@ctu.mrc.ac.uk
Journal: J Thorac Oncol. 2006 Sep;1(7):611-21.
Abstract URL: Click here to view abstract

46. Novel cytotoxic agents for non-small cell lung cancer.

Author: Edelman MJ;
Institution: University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA. medelman@umm.edu
Journal: J Thorac Oncol. 2006 Sep;1(7):752-5.
Abstract URL: Click here to view abstract

47. Immune-modulating vaccines in non-small cell lung cancer.

Author: Nemunaitis J; Murray N;
Institution: Mary Crowley Medical Research Center, Dallas, Texas, USA.
Journal: J Thorac Oncol. 2006 Sep;1(7):756-61.
Abstract URL: Click here to view abstract

48. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.

Author: Noble J; Ellis PM; Mackay JA; Evans WK;
Institution: Hopital Regional de Sudbury Regional Hospital, Regional Cancer Program, Sudbury, ON, Canada.
Journal: J Thorac Oncol. 2006 Nov;1(9):1042-58.
Abstract URL: Click here to view abstract

49. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review.

Author: Pillot G; Siegel BA; Govindan R;
Institution: Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Journal: J Thorac Oncol. 2006 Feb;1(2):152-9.
Abstract URL: Click here to view abstract

50. Adjuvant chemotherapy for resected non-small cell lung cancer.

Author: Booth CM; Shepherd FA;
Institution: Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
Journal: J Thorac Oncol. 2006 Feb;1(2):180-7.
Abstract URL: Click here to view abstract

51. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.

Author: Feld R; Sridhar SS; Shepherd FA; Mackay JA; Evans WK;
Institution: Princess Margaret Hospital, Toronto, Ontario, Canada.
Journal: J Thorac Oncol. 2006 May;1(4):367-76.
Abstract URL: Click here to view abstract

52. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.

Author: Wakelee H; Dubey S; Gandara D;
Institution: Oncology, Stanford University, 875 Blake Wilbur Drive, Room 2233, Stanford, California 94305-5826, USA. hwakelee@stanford.edu
Journal: Oncologist. 2007 Mar;12(3):331-7.
Abstract URL: Click here to view abstract

53. Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis.

Author: Micames CG; McCrory DC; Pavey DA; Jowell PS; Gress FG; Micames CG; McCrory DC; Pavey DA; Jowell PS; Gress FG;
Institution: Duke University Medical Center, Division of Gastroenterology, Box 3913, Durham, NC 27710, USA. Carlos.micames@duke.edu
Journal: Chest. 2007 Feb;131(2):539-48.
Abstract URL: Click here to view abstract

54. Lung cancer.

Author: Ginsberg MS; Grewal RK; Heelan RT; Ginsberg MS; Grewal RK; Heelan RT;
Institution: Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. ginsberm@mskcc.org
Journal: Radiol Clin North Am. 2007 Jan;45(1):21-43.
Abstract URL: Click here to view abstract

55. Innovations in the radiotherapy of non-small cell lung cancer.

Author: Schild SE; Bogart JA;
Institution: North Central Cancer Treatment Group Lung Committee and Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona 85259, USA. sschild@mayo.edu
Journal: J Thorac Oncol. 2006 Jan;1(1):85-92.
Abstract URL: Click here to view abstract

56. Second- and third-line treatments in non-small cell lung cancer.

Author: Kumar A; Wakelee H;
Institution: Stanford Cancer Center, Stanford, CA 94305, USA. hwakelee@stanford.edu
Journal: Curr Treat Options Oncol. 2006 Jan;7(1):37-49.
Abstract URL: Click here to view abstract

57. Comparison of surgical results after pneumonectomy and sleeve lobectomy for non-small cell lung cancer: trends over time and 20-year institutional experience.

Author: Takeda S; Maeda H; Koma M; Matsubara Y; Sawabata N; Inoue M; Tokunaga T; Ohta M;
Institution: Department of General Thoracic Surgery, National Hospital Organization, Toneyama National Hospital, Toneyama 5-1-1, Toyonaka, Osaka 560-8552, Japan. stakeda@toneyama.hosp.go.jp
Journal: Eur J Cardiothorac Surg. 2006 Mar;29(3):276-80. Epub 2006 Jan 24.
Abstract URL: Click here to view abstract

58. Surgery versus radiosurgery for patients with a solitary brain metastasis from non-small cell lung cancer.

Author: Fuentes R; Bonfill X; Exposito J;
Institution: Institut Catala d'Oncologia, Avda Franca, s/n, Girona, Spain, 17007. rfuentes@ico.scs.es
Journal: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004840.
Abstract URL: Click here to view abstract

59. Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?

Author: Saha A; Rudd R;
Institution: Medical Oncology, St Bartholomew's Hospital, London, UK. antonio.saha@cancer.org.uk
Journal: Expert Rev Anticancer Ther. 2006 Feb;6(2):165-73.
Abstract URL: Click here to view abstract

60. Second-line treatment options in advanced non-small cell lung cancer: current status.

Author: Cullen M;
Institution: Cancer Centre, University Hospital Birmingham, Birmingham, UK. michael.cullen@uhb.nhs.uk
Journal: Semin Oncol. 2006 Feb;33(1 Suppl 1):S3-8.
Abstract URL: Click here to view abstract

61. Non-small-cell lung cancer in the elderly.

Author: Meriggi F; Zaniboni A;
Institution: Oncology Department, Poliambulanza, Via Bissolati 57, 25124 Brescia, Italy. zanib@numerica.it
Journal: Crit Rev Oncol Hematol. 2006 Feb;57(2):183-90. Epub 2005 Oct 5.
Abstract URL: Click here to view abstract

62. Management of early-stage lung cancer: past, present, and future adjuvant trials.

Author: Strauss GM;
Institution: Lung Cancer Program, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.
Journal: Oncology (Williston Park). 2006 Nov;20(13):1651-63; discussion 1663-4, 1666, 1669-70 passim.
Abstract URL: Click here to view abstract

63. A review of topoisomerase inhibition in lung cancer.

Author: Chhatriwala H; Jafri N; Salgia R;
Institution: Department of Medicine, Griffin Hospital, Derby, Connecticut, and Boston University School of Medicine, MA, USA.
Journal: Cancer Biol Ther. 2006 Dec;5(12):1600-7. Epub 2006 Dec 29.
Abstract URL: Click here to view abstract

64. Recent advances in targeted therapy for non-small cell lung cancer.

Author: Ramalingam S; Belani CP;
Institution: University of Pittsburgh School of Medicine, Division of Hematology-Oncology, Department of Medicine, Pittsburgh, PA, USA. ramalingams@upmc.edu
Journal: Expert Opin Ther Targets. 2007 Feb;11(2):245-57.
Abstract URL: Click here to view abstract

65. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.

Author: Chou LS; Garey J; Oishi K; Kim E;
Institution: University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Clin Lung Cancer. 2006 Dec;8 Suppl 1:S15-22.
Abstract URL: Click here to view abstract

66. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.

Author: Herbst RS;
Institution: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. rherbst@mdanderson.or
Journal: Clin Lung Cancer. 2006 Dec;8 Suppl 1:S23-30.
Abstract URL: Click here to view abstract

67. Update in the treatment of brain metastases from lung cancer.

Author: Schwer AL; Gaspar LE; Schwer AL; Gaspar LE;
Institution: University of Colorado Health Sciences Center, Aurora, CO 80010, USA.
Journal: Clin Lung Cancer. 2006 Nov;8(3):180-6.
Abstract URL: Click here to view abstract

68. Second-line treatment of small-cell lung cancer.

Author: MacCallum C; Gillenwater HH;
Institution: Division of Hematology and Oncology, University of Virginia, Charlottesville, VA 22908, USA.
Journal: Curr Oncol Rep. 2006 Jul;8(4):258-64.
Abstract URL: Click here to view abstract

69. Surgery of non-small cell lung cancer in the elderly.

Author: Spaggiari L; Scanagatta P;
Institution: Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy. lorenzo.spaggiari@ieo.it
Journal: Curr Opin Oncol. 2007 Mar;19(2):84-91.
Abstract URL: Click here to view abstract

70. Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer.

Author: De Pauw R; van Meerbeeck JP;
Institution: Department of Thoracic Oncology, University Hospital Ghent, Belgium.
Journal: Curr Opin Oncol. 2007 Mar;19(2):92-7.
Abstract URL: Click here to view abstract

71. Combined targeted therapies in non-small cell lung cancer: a winner strategy?

Author: Cascone T; Gridelli C; Ciardiello F;
Institution: Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy.
Journal: Curr Opin Oncol. 2007 Mar;19(2):98-102.
Abstract URL: Click here to view abstract

72. Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers.

Author: Huang CL; Yokomise H; Miyatake A;
Institution: Second Department of Surgery, Faculty of Medicine, Kagawa University, 1750-1, Mikicho, Kita-gun, Kagawa 761-0793, Japan. chuang@kms.ac.jp
Journal: Future Oncol. 2007 Feb;3(1):83-93.
Abstract URL: Click here to view abstract

73. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis.

Author: Mell LK; Malik R; Komaki R; Movsas B; Swann RS; Langer C; Antonadou D; Koukourakis M; Mundt AJ;
Institution: Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA. lmell@radonc.uchicago.edu
Journal: Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):111-8. Epub 2007 Feb 7.
Abstract URL: Click here to view abstract

74. Lung cancer in never smokers: a review.

Author: Subramanian J; Govindan R;
Institution: Department of Medicine and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA.
Journal: J Clin Oncol. 2007 Feb 10;25(5):561-70.
Abstract URL: Click here to view abstract

75. Use of novel second-line targeted therapies in non-small cell lung cancer.

Author: Massarelli E; Herbst RS;
Institution: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Semin Oncol. 2006 Feb;33(1 Suppl 1):S9-16.
Abstract URL: Click here to view abstract

76. Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies.

Author: de Marinis F; De Santis S; De Petris L;
Institution: 5th Pneumo-oncology Unit, Department of Oncology, S. Camillo-Forlanini Hospitals, Rome, Italy. demarinis.filippo@virgilio.it
Journal: Semin Oncol. 2006 Feb;33(1 Suppl 1):S17-24.
Abstract URL: Click here to view abstract

77. Advances in chemotherapy of non-small cell lung cancer.

Author: Molina JR; Adjei AA; Jett JR; Molina JR; Adjei AA; Jett JR; Molina JR; Adjei AA; Jett JR;
Institution: Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. molina.julian@mayo.edu
Journal: Chest. 2006 Oct;130(4):1211-9.
Abstract URL: Click here to view abstract

78. Recent developments in the chemotherapeutic options for nonsmall cell lung cancer.

Author: Ibrahim MN; Abdullah Z; Martin MJ;
Institution: Sligo General Hospital, The Medical Oncology Department, The Mall, Sligo, Co. Sligo, Ireland.
Journal: Expert Rev Anticancer Ther. 2006 Oct;6(10):1397-410.
Abstract URL: Click here to view abstract

79. Optimizing therapy in previously treated non-small cell lung cancer.

Author: Miller VA;
Institution: Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. millerv@mskcc.org
Journal: Semin Oncol. 2006 Feb;33(1 Suppl 1):S25-31.
Abstract URL: Click here to view abstract

80. Lung cancer in the elderly.

Author: Gridelli C; Langer C; Maione P; Rossi A; Schild SE; Gridelli C; Langer C; Maione P; Rossi A; Schild SE;
Institution: Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy. cgridelli@libero.it
Journal: J Clin Oncol. 2007 May 10;25(14):1898-907.
Abstract URL: Click here to view abstract

81. Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer.

Author: Temel JS; Pirl WF; Lynch TJ;
Institution: Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA. jtemel@partners.org
Journal: Clin Lung Cancer. 2006 Jan;7(4):241-9.
Abstract URL: Click here to view abstract

82. Prophylactic cranial irradiation versus observation in stage III non-small-cell lung cancer.

Author: Gore E;
Institution: Radiation Oncology, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226, USA. egore@radonc.mcw.edu
Journal: Clin Lung Cancer. 2006 Jan;7(4):276-8.

83. New antiangiogenetic agents and non-small cell lung cancer.

Author: Gridelli C; Rossi A; Maione P;
Institution: Division of Medical Oncology, S.G. Moscati Hospital, Contrada Amoretta, Avellino, Italy. cgridelli@libero.it
Journal: Crit Rev Oncol Hematol. 2006 Oct;60(1):76-86. Epub 2006 Jul 13.
Abstract URL: Click here to view abstract